Urinary Tract Disorders

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/af4d88/global_bladder_can) has announced the addition of the "Global Bladder Cancer Drug Pipeline Capsule - 2012" report to their offering. Fore Pharma's latest report 'Global Bladder Cancer Drug Pipeline...

BIOGGIO, Switzerland -- Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised 7.5 Million CHF from existing investors...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/a0b7d0/urinary_tract_infe) has announced the addition of Global Markets Direct's new report "Urinary Tract Infections - Pipeline Review, H2 2011" to their offering. Global Markets Direct's, 'Urinary Tract Infections...

Company Monitor Indigenous Companies Strengths Strong position in its core markets of the Czech Republic and Slovakia, with growth targeted in Romania. The acquisition of Sicomed in Romania in late 2005 provided a...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/082baa/interstitial_cysti) has announced the addition of GlobalData's new report "Interstitial Cystitis Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, Interstitial Cystitis Global Clinical...

Millennium Research Group's New Physician Forum Report Provides Details of Physician Attitudes and Choices TORONTO -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, while some physicians...

Pilot study demonstrates CEL-031 efficacy in animal bladder cancer model ROCKVILLE, Md. -- Celek Pharmaceuticals today announced that the National Cancer Institute (NCI) has awarded the Company a Phase I Small Business Innovation...

SOLESTA([R]) and DEFLUX ([R]) Expand Salix's Product Portfolio RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Oceana Therapeutics, LLC today closed a transaction whereby Salix acquired all of the outstanding stock of Oceana...

Antares' oxybutynin product is a clear, odorless topical gel available in a convenient, metered-dose pump that has demonstrated to be an effective and safe treatment for overactive bladder, or OAB. Because the active...

Lisdexamfetamine dimesylate is a prescription medicine currently approved in the US, Canada, and Brazil for the treatment of Attention- Deficit/Hyperactivity Disorder, or ADHD. Vyvanse should only be used to treat ADHD. Vyvanse is...

The study showed that reductions in blood sugar levels, or glycosylated hemoglobin levels, or HbA1c, seen at 24 weeks with the investigational compound dapagliflozin added to existing glimepiride, or sulphonylurea, therapy, compared to...

LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the initiation of a pivotal Phase 3 trial of CXA-201 (ceftolozane/tazobactam) in patients with complicated intra-abdominal infections (cIAI). CXA-201 is being developed as...

CHESHIRE, Conn. -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of new data that underscore the severity of paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder. PNH is...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/7ef084/bladder_cancer_glo) has announced the addition of GlobalData 's new report "Bladder Cancer Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, Bladder Cancer Global...

Innovative Endoscopes with Improved Video Capabilities and Holmium Lasers to Show Greatest Growth, According to Millennium Research Group TORONTO -- According to Millennium Research Group (MRG), the global authority on medical technology market...

DUBAI, United Arab Emirates -- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a Phase 3 clinical study which showed that reductions in blood sugar levels (glycosylated hemoglobin...

Analysis to Include Epidemiology and Primary Research with Urologists and Oncologists to Guide Pharmaceutical Companies in Understanding Opportunities and Challenges of the Bladder Cancer Drug Market BURLINGTON, Mass. -- Decision Resources, one of...

NEW YORK -- Pfizer Inc. (NYSE: PFE) announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 - Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients...

Part A of the study has been completed, having met its scientific and clinical goals of establishing primary proof of concept. Part B of the study currently is underway using an advanced formulation...